Immune-related Bell’s palsy in melanoma patients treated with immune checkpoint inhibitors

Teresa Beninato(Fondazione IRCCS Istituto Nazionale dei Tumori), Carolina Cimminiello(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Valeri(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Fucà(AstraZeneca (Spain)), Irene Vetrano(Melanoma Institute Australia), Francesco Nesa(Ospedale Maggiore), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori)
Melanoma Research
January 22, 2021
10.1097/cmr.0000000000000715
Cited by 5

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Interleukin-12: Biological Properties and Clinical Application
|Clinical Cancer Research|2007|606
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2020|530
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2017|501